BioVie to present Long COVID trial data at NIH-backed workshop
BioVie Inc (BIVI) will present Phase 2 trial data for its drug bezisterim at a US government-backed Long COVID workshop. The ADDRESS-LC study showed improvements in fatigue, post-exertional malaise, and cognitive function in severe cases. The trial, funded by a $13.13M grant, enrolled 200 adults with Long COVID. BioVie aims to identify patient subgroups for future Phase 3 trials.
How this was made
The 30-second read
Why it matters
The disclosed Phase 2 ADDRESS-LC pattern suggests potential efficacy, especially in patients with higher baseline fatigue, post-exertional malaise, or cognitive impairment, and could inform confirmatory Phase 3 design.
Market read
This is a pre-readout catalyst for BioVie’s Long COVID program, potentially improving near-term sentiment ahead of the Nov 5 presentation.
What to watch
Traders may discount the signal because the article does not provide effect sizes, p-values per endpoint, or details on how the 22 outcome measures performed overall beyond a general 'consistent trend' description.
Background
The RECOVER-TLC initiative is NIH-backed and aims to accelerate Long COVID therapeutics; BioVie’s bezisterim is an investigational oral drug targeting blood-brain barrier crossing, inflammation reduction, and insulin sensitivity.
Ticker impact
BioVie invited to present Phase 2 ADDRESS-LC bezisterim Long COVID results, including a consistent improvement trend vs placebo and safety similar to placebo.
Likely modest upward bias as traders price in improved efficacy signal and a clearer path to Phase 3, tempered by the non-pivotal nature of the event.
The article discloses new trial findings framing (improvement trend, baseline symptom subgroup benefit, safety parity) but does not announce regulatory action or a definitive Phase 3 start date.
Market effects
Adds incremental sentiment to the Long COVID treatment pipeline and to CNS/inflammation-focused biotech narratives, though impact is likely limited without Phase 3 confirmation.
Bethesda, US-hosted NIH workshop may attract additional US clinical attention but is not a macro driver.
Long COVID remains an international unmet-need area; incremental data can influence global biotech sentiment but is unlikely to move broad markets.
Counterpoint
A Phase 2 signal presented at a workshop may not change valuation materially if endpoints are not clearly definitive or if placebo effects and subgroup selection risk remain.
Key entities
- companyBioVie Inc
Clinical-stage biopharmaceutical company presenting Phase 2 ADDRESS-LC Long COVID trial results for bezisterim.
- drugbezisterim
Investigational oral therapy being evaluated in the ADDRESS-LC Phase 2 trial for Long COVID.
- eventRECOVER-TLC Hybrid Workshop
NIH-backed workshop where BioVie will present the trial findings on Nov 5.
- government_research_bodyNational Institute of Allergy and Infectious Diseases (NIAID)
Hosts the workshop as part of the NIH ecosystem.
